No Data
Express News | Palatin Technologies Enters Warrant Inducement Agreement With Institutional Investor To Exercise 3,233,277 Shares Issued In November 2022 And October 2023, Raising $6.1M
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds
Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based...
Express News | Palatin Technologies Has Initiated Phase 2 Study Of Bremelanotide, A Melanocortin 4 Receptor, Co-administered With A Phosphodiesterase 5 Inhibitor, For Erectile Dysfunction In Patients That Do Not Respond To PDE5i Monotherapy. Topline Data Is Expected By
Express News | Palatin Technologies: Potential Phase 3 Clinical Study in Ed Patients Who Do Not Respond to Pde5I Monotherapy to Start in H1 2025
Express News | Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered With a Pde5I for the Treatment of Erectile Dysfunction (Ed)
Sector Update: Health Care Stocks Ease Late Afternoon
Health care stocks were softer late Wednesday afternoon, with the NYSE Health Care Index decreasing 0.3% and the Health Care Select Sector SPDR Fund (XLV) down 0.1%. The iShares Biotechnology ETF (IBB